Meeting
2019 ASCO Annual Meeting
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
Authors
Takeo Fujii
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Takeo Fujii , Hiroko Masuda , Yee Chung Cheng , Fei Yang , Aysegul A. Sahin , Yasuto Naoi , Yuki Matsunaga , Akshara Singareeka Raghavendra , Arup Kumar Sinha , Jose R. Espinosa Fernandez , Anjali James , Keisuke Yamagishi , Debu Tripathy , Sachiyo Tada , Rubie S. Jackson , Shinzaburo Noguchi , Seigo Nakamura , Jared David Acoba , Naoto T. Ueno , Tomoko Matsushima
Organizations
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Univ of Texas MD Anderson Cancer Ctr, Houston, TX, Medical College of Wisconsin, Menomonee Falls, WI, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan, Showa University, Tokyo, Japan, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, Sysmex Corporation, Kobe, Japan, The Rebecca Fortney Breast Center, Anne Arundel Medical Center, Annapolis, MD, Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan, University of Hawaii Cancer Center, Honolulu, HI, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, Central Research Laboratories, Sysmex Corporation, Kobe, Japan
Research Funding
Other
Background: The TAILORx trial demonstrated that adjuvant endocrine and chemoendocrine therapies had similar efficacy in patients with hormone receptor-positive, HER2-negative, node-negative breast cancer with an Oncotype DX recurrence score (RS) of 11-25. However, a predictive strategy is needed to identify patients with intermediate RS who may benefit from adjuvant chemoendocrine therapy. Curebest 95GC Breast (95GC) is a 95-gene signature that can stratify patients into two groups with high (95GC-H) and low (95GC-L) groups to predict the risk of recurrence. Our primary objective was to show that 95GC can classify patients with intermediate RS into binary recurrence risk groups. Methods: Patients with ER-positive, HER2-negative, node-negative invasive breast cancer and RS 11-30 who underwent definitive surgery and adjuvant endocrine therapy were included. RNA was derived from archived formalin-fixed, paraffin-embedded samples, and 95GC was calculated as reported previously. The Fisher exact and Brunner-Munzel tests were used to compare variables between 95GC groups. A Kaplan-Meier estimate with a log-rank test was used for recurrence-free survival (RFS) analysis. Results: The analysis included 178 patients from five institutions. The 5-year RFS rate in patients with RS 18-30 was higher in the 95GC-L group (n = 129, 96.3%) than in the 95GC-H group (n = 49, 90.9%; p = 0.002), which was consistent with results in an independent Japanese population (n = 224; p < 0.001). RFS rates significantly differed between the groups among patients with RS 11-25 as well (95GC-L, 97.4%; 95GC-H, 87.1%; p = 0.001). RFS rates did not differ between patients with RS 18-25 (94.8%) and those with RS 26-30 (93.8%; p = 0.33). Conclusions: 95GC can predict recurrence risk in patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS. Further prospective retrospective studies in the TAILORx population are warranted to confirm that 95GC can identify patients who may benefit from adjuvant chemoendocrine therapy.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 542)
DOI
10.1200/JCO.2019.37.15_suppl.542
Abstract #
542
Poster Bd #
34
Abstract Disclosures
Similar Abstracts
Abstract
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Abstract
2018 ASCO Annual Meeting
Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: Experience of Kuwait Cancer Control Center.
First Author: Mohamed Salah Fayaz
Abstract
2023 ASCO Annual Meeting
Factors associated with oncotype and recurrence among a diverse breast cancer population seeking care at an urban safety-net hospital.
First Author: Judy Jiaqi Wang
Abstract
2024 ASCO Annual Meeting
Association of N-adhesin and focal adhesion kinase with frequency of tumor spread through the airspace (STAS) in stage I lung carcinoma and correlation with recurrence.
First Author: Hongbing Liu